Efficacy of Fluoxetine and (

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Post-traumatic stress disorder (PTSD) affects millions, with current treatments offering limited remission rates.
• Existing PTSD therapies struggle with persistent re-experiencing and fear generalization symptoms.
• There is a critical need for novel pharmacological interventions for stress-related disorders.

Purpose of the Study:

• To evaluate the efficacy of acute ketamine and chronic fluoxetine (FLX) in a rodent model of PTSD.
• To assess the impact of these treatments on fear memory and fear generalization behaviors.
• To explore potential improvements over current PTSD treatment options.

Main Methods:

• Rodents underwent fear conditioning (FC) involving auditory cues and foot shocks.
• Treatments with acute ketamine and/or chronic fluoxetine were administered post-FC.
• Fear and anxiety behaviors were measured during re-exposure to stimuli and via open field tests (OFT).

Main Results:

• The combination of acute ketamine and chronic FLX reduced fear memory behaviors at 2 weeks post-treatment.
• Fluoxetine monotherapy demonstrated the most significant reduction in fear generalization behaviors.
• Neither treatment combination nor monotherapy fully resolved anxiety or fear generalization in the OFT.

Conclusions:

• Combined acute ketamine and chronic FLX show promise for mitigating fear memory deficits in PTSD models.
• Chronic FLX alone appears effective for reducing fear generalization, a key PTSD symptom.
• Further research is essential to optimize treatment protocols and understand underlying molecular mechanisms.